These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33297341)

  • 1. Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP
    Edupuganti S; C De Rosa S; Elizaga M; Lu Y; Han X; Huang Y; Swann E; Polakowski L; A Kalams S; Keefer M; Maenza J; C Wise M; Yan J; Morrow MP; Khan AS; Boyer JD; Humeau L; White S; Sardesai NY; Bagarazzi ML; Gilbert PB; Kublin JG; Corey L; Weiner DB; On Behalf Of The Hvtn Study Team ; The Niaid-Funded Hiv Vaccine Trials Network
    Vaccines (Basel); 2020 Dec; 8(4):. PubMed ID: 33297341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust antibody and cellular responses induced by DNA-only vaccination for HIV.
    De Rosa SC; Edupuganti S; Huang Y; Han X; Elizaga M; Swann E; Polakowski L; Kalams SA; Keefer MC; Maenza J; Lu Y; Wise MC; Yan J; Morrow MP; Khan AS; Boyer JD; Humeau L; White S; Pensiero M; Sardesai NY; Bagarazzi ML; Weiner DB; Ferrari G; Tomaras GD; Montefiori DC; Corey L; McElrath MJ;
    JCI Insight; 2020 Jul; 5(13):. PubMed ID: 32437332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
    Hannaman D; Dupuy LC; Ellefsen B; Schmaljohn CS
    Vaccine; 2016 Jun; 34(31):3607-12. PubMed ID: 27206386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
    Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
    PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers.
    Diehl MC; Lee JC; Daniels SE; Tebas P; Khan AS; Giffear M; Sardesai NY; Bagarazzi ML
    Hum Vaccin Immunother; 2013 Oct; 9(10):2246-52. PubMed ID: 24051434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.
    Kalams SA; Parker SD; Elizaga M; Metch B; Edupuganti S; Hural J; De Rosa S; Carter DK; Rybczyk K; Frank I; Fuchs J; Koblin B; Kim DH; Joseph P; Keefer MC; Baden LR; Eldridge J; Boyer J; Sherwat A; Cardinali M; Allen M; Pensiero M; Butler C; Khan AS; Yan J; Sardesai NY; Kublin JG; Weiner DB;
    J Infect Dis; 2013 Sep; 208(5):818-29. PubMed ID: 23840043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial.
    Mpendo J; Mutua G; Nanvubya A; Anzala O; Nyombayire J; Karita E; Dally L; Hannaman D; Price M; Fast PE; Priddy F; Gelderblom HC; Hills NK
    PLoS One; 2020; 15(5):e0233151. PubMed ID: 32469893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.
    Jacobson JM; Zheng L; Wilson CC; Tebas P; Matining RM; Egan MA; Eldridge J; Landay AL; Clifford DB; Luetkemeyer AF; Tiu J; Martinez AL; Janik J; Spitz TA; Hural J; McElrath J; Frahm N;
    J Acquir Immune Defic Syndr; 2016 Feb; 71(2):163-71. PubMed ID: 26761518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
    Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
    Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
    Vasan S; Hurley A; Schlesinger SJ; Hannaman D; Gardiner DF; Dugin DP; Boente-Carrera M; Vittorino R; Caskey M; Andersen J; Huang Y; Cox JH; Tarragona-Fiol T; Gill DK; Cheeseman H; Clark L; Dally L; Smith C; Schmidt C; Park HH; Kopycinski JT; Gilmour J; Fast P; Bernard R; Ho DD
    PLoS One; 2011; 6(5):e19252. PubMed ID: 21603651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults.
    Recuenco S; Warnock E; Osinubi MOV; Rupprecht CE
    Vaccine; 2017 Aug; 35(34):4315-4320. PubMed ID: 28688782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
    Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stöhr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandström E; Lyamuya E;
    PLoS One; 2018; 13(11):e0206838. PubMed ID: 30496299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
    Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
    PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Safety and Immunogenicity of GTU
    Haidari G; Day S; Wood M; Ridgers H; Cope AV; Fleck S; Yan C; Reijonen K; Hannaman D; Spentzou A; Hayes P; Vogt A; Combadiere B; Cook A; McCormack S; Shattock RJ
    Front Immunol; 2019; 10():2911. PubMed ID: 31921170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
    Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques.
    Hirao LA; Wu L; Khan AS; Hokey DA; Yan J; Dai A; Betts MR; Draghia-Akli R; Weiner DB
    Vaccine; 2008 Jun; 26(25):3112-20. PubMed ID: 18430495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers.
    Tebas P; Kraynyak KA; Patel A; Maslow JN; Morrow MP; Sylvester AJ; Knoblock D; Gillespie E; Amante D; Racine T; McMullan T; Jeong M; Roberts CC; Park YK; Boyer J; Broderick KE; Kobinger GP; Bagarazzi M; Weiner DB; Sardesai NY; White SM
    J Infect Dis; 2019 Jul; 220(3):400-410. PubMed ID: 30891607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.
    Garg S; Thongcharoen P; Praphasiri P; Chitwarakorn A; Sathirapanya P; Fernandez S; Rungrojcharoenkit K; Chonwattana W; Mock PA; Sukwicha W; Katz JM; Widdowson MA; Curlin ME; Gibbons RV; Holtz TH; Dawood FS; Olsen SJ
    Clin Infect Dis; 2016 Feb; 62(3):383-391. PubMed ID: 26486702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.
    Ake JA; Schuetz A; Pegu P; Wieczorek L; Eller MA; Kibuuka H; Sawe F; Maboko L; Polonis V; Karasavva N; Weiner D; Sekiziyivu A; Kosgei J; Missanga M; Kroidl A; Mann P; Ratto-Kim S; Anne Eller L; Earl P; Moss B; Dorsey-Spitz J; Milazzo M; Laissa Ouedraogo G; Rizvi F; Yan J; Khan AS; Peel S; Sardesai NY; Michael NL; Ngauy V; Marovich M; Robb ML
    J Infect Dis; 2017 Nov; 216(9):1080-1090. PubMed ID: 28968759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.